Form 4: Aprea Therapeutics Director Equity Grant

Director Michael Grissinger received a grant of restricted stock units and stock options as part of his board compensation.

Summary

• Director Michael Grissinger was granted 3,135 restricted stock units (RSUs) on June 16, 2026.
• The director also received 12,555 stock options with an exercise price of $0.7293 per share.
• Both the RSUs and the stock options are scheduled to vest in full on June 16, 2027, contingent upon continued service on the board.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Equity-based compensation aligns the director's interests with those of shareholders.
• The grant structure encourages long-term retention of board members.

Negatives

• The issuance of new equity results in minor dilution to existing shareholders.

Risks

• Vesting is subject to continued service, creating a dependency on the director's ongoing tenure.

Future Outlook

The equity grants are subject to standard vesting schedules over a one-year period ending June 16, 2027.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise.

Comparison to Industry Standards

• The use of a one-year cliff vesting period for director equity is consistent with standard corporate governance practices for small-cap biotech firms.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of equity awards on June 16, 2027.

Key Dates

Keywords

Aprea Therapeutics, APRE, Form 4, Insider Trading, Equity Compensation, Director Compensation